Celonic Group to Manufacture CureVac’s mRNA COVID Vaccine Candidate

News
Article

Celonic will manufacture CvnCoV at its facility in Germany.

Biopharmaceutical company CureVac and contract development and manufacturing organization (CDMO) Celonic Group announced in a March 30, 2021 press release that they have entered into a commercial supply agreement to produce CureVac’s mRNA-based COVID-19 vaccine candidate, CvnCoV, at Celonic’s commercial manufacturing facility for biologics and advanced therapy medicinal products (ATMPs) in Heidelberg, Germany.

Celonic will be prepared to manufacture more than 100 million doses of CvnCoV, with more than 50 million doses expected to be produced before the end of 2021. Under the terms of the initial agreement, technology and knowledge transfer is already underway. The commercial supply agreement includes manufacturing of the mRNA drug substance as well as lipid nanoparticle formulation of the bulk drug product.

CureVac’s overall capacity, throughout its European manufacturing network, is expected to be up to 300 million doses in 2021.

“Manufacturing of sufficient quantities of vaccine is critical to combating the COVID-19 pandemic,” said Dr. Florian von der Mülbe, chief production officer of CureVac, in the press release. “With this partnership, we are further extending our integrated European manufacturing network, reinforcing the overall production capacity for our COVID-19 vaccine candidate, CVnCoV.”

“We have invested heavily to support our partners in bringing novel COVID-19 therapeutics and vaccines to patients, at an accelerated pace,” added Dr. Konstantin Matentzoglu, CEO of Celonic, in the press release.

Source: CureVac

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content